In this issue
Progressive kidney diseases result in interstitial fibrosis, and successful therapies must abrogate this accumulation of scar. However, because clinical markers of progression change slowly, and frequently repeated histologic investigation is not practical, success has been difficult to assess in clinical trials and practice. Baues et al. addressed this, describing the results of optical imaging for collagen types I and III (scar collagen) using a fluorescently tagged molecular probe (collagen-binding adhesion protein CNA35).
Source: Kidney International - Category: Urology & Nephrology Tags: In This Issue Source Type: research
More News: Clinical Trials | Urology & Nephrology